Guotai CSI BIOMEDICINE ETF (512290) Rises 1.41%, with Latest Margin Buying Amount Reaching RMB 9.8868 Million

NewTimeSpace (newtimespace.com) News,–As of 09:36 on July 29, 2026, Guotai Biopharmaceutical ETF (512290) rose 1.41%, with its latest price at RMB 1.01. Over a longer horizon, as of July 28, 2026, the ETF had accumulated a gain of 10.80% over the past month.

In terms of liquidity, Guotai Biopharmaceutical ETF recorded a turnover rate of 0.40% during the session, with trading volume reaching RMB 14.3463 million. Over a longer period, as of July 28, the ETF’s average daily turnover over the past month was RMB 239 million.

In terms of scale, the latest asset size of Guotai Biopharmaceutical ETF stood at RMB 3.548 billion. (Data source: Wind)

Data shows that leveraged funds are continuing to position themselves. The latest margin buying amount for Guotai Biopharmaceutical ETF reached RMB 9.8868 million, with its latest margin balance standing at RMB 126 million. (Data source: Wind)

As of July 28, the net value of Guotai Biopharmaceutical ETF had risen 19.58% over the past 2 years. In terms of return capability, as of July 28, 2026, since its inception, the ETF achieved a highest single‑month return of 23.26%, a longest consecutive winning streak of 8 months with a cumulative gain of 109.28%, and an average monthly return of 6.39% during up months. As of July 28, 2026, the ETF’s 3‑month excess annualized return over its benchmark was 4.79%.

In terms of drawdown, as of July 28, 2026, the ETF’s half‑year drawdown relative to its benchmark was 0.13%. The recovery period after drawdown was 36 days.

On fees, Guotai Biopharmaceutical ETF charges a management fee of 0.50% and a custody fee of 0.10%.

On tracking accuracy, as of July 28, 2026, the ETF’s 3‑year tracking error was 0.036%.

Guotai Biopharmaceutical ETF closely tracks the CSI Biopharmaceutical Index. The index selects listed company securities that provide products and services such as cell therapy, gene sequencing, blood products, biotech drugs, vaccines, and in vitro diagnostics as index samples, reflecting the overall performance of listed companies in the biopharmaceutical industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.